FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4474461> ?p ?o ?g. }

• W4474461 endingPage "4989" @default.
• W4474461 startingPage "4979" @default.
• W4474461 abstract "Timed sequencing of cycles of induction chemotherapy in acute myeloid leukemia (AML) has been proposed as a way to achieve maximal leukemic cell kill through recruitment and synchronization of residual neoplastic cells. Furthermore, whether intensive induction therapy should be continued in the presence of profound myelosuppression is an important question. The Children's Cancer Group (CCG) conducted a prospective randomized trial in which 589 patients with AML were randomized at diagnosis to one of two induction approaches involving a 4-day cycle of five active chemotherapeutic agents, with the second cycle administered either 10 days after the first cycle, despite low or dropping blood counts (intensive timing), or 14 days or later from the beginning of the first cycle, depending on bone marrow status (standard timing). All patients achieving remission received a total of four cycles of induction therapy. They were then allocated to allogeneic bone marrow transplantation (BMT) if a compatible family donor was present or randomized to aggressive nonmyeloablative therapy or to myeloablative therapy with purged autologous BMT rescue. The three postremission arms remain coded. Induction success and median days to complete induction were similar for the 295 patients randomized to the intensive timing arm (75%, 99 days) compared with the 294 patients randomized to the standard timing arm (70%, 105 days; P = .18 for remission). However, a marked improvement in outcome was demonstrated in patients randomized to the intensive timing arm, with an actuarial event-free survival at 3 years of 42% +/- 7% (95% confidence interval [CI]) versus 27% +/- 6% for patients on the standard timing arm (P = .0005). Disease-free survival results at 3 years from the end of induction were superior for patients receiving intensively timed induction therapy (N = 211), 55% +/- 9% versus 37% +/- 9% for standard timing patients (N = 195, P = .0002), with a median follow-up from achieving remission of 28 months. Superior results were documented for patients receiving intensive timing irrespective of the postremission therapy to which they were allocated. Intensively timed induction therapy for patients with AML markedly improves event-free survival, even for patients undergoing myeloablative therapy with BMT rescue. Without controlling for the type of induction therapy received, results of various BMT studies in AML comparing different preparative regimens will be difficult to interpret." @default.
• W4474461 created "2016-06-24" @default.
• W4474461 creator A5000374788 @default.
• W4474461 creator A5000624483 @default.
• W4474461 creator A5006788534 @default.
• W4474461 creator A5007262193 @default.
• W4474461 creator A5009084505 @default.
• W4474461 creator A5018786888 @default.
• W4474461 creator A5025381113 @default.
• W4474461 creator A5025630600 @default.
• W4474461 creator A5026088642 @default.
• W4474461 creator A5052896867 @default.
• W4474461 creator A5060477535 @default.
• W4474461 creator A5061379753 @default.
• W4474461 creator A5062054752 @default.
• W4474461 date "1996-06-15" @default.
• W4474461 modified "2023-10-01" @default.
• W4474461 title "Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group" @default.
• W4474461 cites W1481564836 @default.
• W4474461 cites W1585733692 @default.
• W4474461 cites W1835148062 @default.
• W4474461 cites W1864995945 @default.
• W4474461 cites W1870350942 @default.
• W4474461 cites W1912991550 @default.
• W4474461 cites W1937764639 @default.
• W4474461 cites W1942780970 @default.
• W4474461 cites W1971387320 @default.
• W4474461 cites W1974801185 @default.
• W4474461 cites W1977797185 @default.
• W4474461 cites W2016162177 @default.
• W4474461 cites W2040135550 @default.
• W4474461 cites W2060878870 @default.
• W4474461 cites W2083616014 @default.
• W4474461 cites W2095002555 @default.
• W4474461 cites W2095523909 @default.
• W4474461 cites W2118389150 @default.
• W4474461 cites W2142341669 @default.
• W4474461 cites W2150113701 @default.
• W4474461 cites W2156467573 @default.
• W4474461 cites W2157633619 @default.
• W4474461 cites W2187668060 @default.
• W4474461 cites W2218136981 @default.
• W4474461 cites W2266287318 @default.
• W4474461 cites W2267533092 @default.
• W4474461 cites W2272218722 @default.
• W4474461 cites W2318674152 @default.
• W4474461 cites W2339392195 @default.
• W4474461 cites W2396527347 @default.
• W4474461 cites W2409849732 @default.
• W4474461 cites W2412055789 @default.
• W4474461 cites W2416376177 @default.
• W4474461 cites W2418923041 @default.
• W4474461 cites W2462871550 @default.
• W4474461 cites W31750938 @default.
• W4474461 cites W40973501 @default.
• W4474461 cites W63132846 @default.
• W4474461 cites W66769540 @default.
• W4474461 cites W187925606 @default.
• W4474461 cites W2313308602 @default.
• W4474461 cites W2410703707 @default.
• W4474461 doi "https://doi.org/10.1182/blood.v87.12.4979.bloodjournal87124979" @default.
• W4474461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8652810" @default.
• W4474461 hasPublicationYear "1996" @default.
• W4474461 type Work @default.
• W4474461 sameAs 4474461 @default.
• W4474461 citedByCount "318" @default.
• W4474461 countsByYear W44744612012 @default.
• W4474461 countsByYear W44744612013 @default.
• W4474461 countsByYear W44744612014 @default.
• W4474461 countsByYear W44744612015 @default.
• W4474461 countsByYear W44744612016 @default.
• W4474461 countsByYear W44744612017 @default.
• W4474461 countsByYear W44744612018 @default.
• W4474461 countsByYear W44744612019 @default.
• W4474461 countsByYear W44744612020 @default.
• W4474461 countsByYear W44744612021 @default.
• W4474461 countsByYear W44744612022 @default.
• W4474461 crossrefType "journal-article" @default.
• W4474461 hasAuthorship W4474461A5000374788 @default.
• W4474461 hasAuthorship W4474461A5000624483 @default.
• W4474461 hasAuthorship W4474461A5006788534 @default.
• W4474461 hasAuthorship W4474461A5007262193 @default.
• W4474461 hasAuthorship W4474461A5009084505 @default.
• W4474461 hasAuthorship W4474461A5018786888 @default.
• W4474461 hasAuthorship W4474461A5025381113 @default.
• W4474461 hasAuthorship W4474461A5025630600 @default.
• W4474461 hasAuthorship W4474461A5026088642 @default.
• W4474461 hasAuthorship W4474461A5052896867 @default.
• W4474461 hasAuthorship W4474461A5060477535 @default.
• W4474461 hasAuthorship W4474461A5061379753 @default.
• W4474461 hasAuthorship W4474461A5062054752 @default.
• W4474461 hasBestOaLocation W44744611 @default.
• W4474461 hasConcept C121608353 @default.
• W4474461 hasConcept C126322002 @default.
• W4474461 hasConcept C141071460 @default.
• W4474461 hasConcept C143998085 @default.
• W4474461 hasConcept C168563851 @default.
• W4474461 hasConcept C2776611710 @default.

• next